Evaluating novel radiological and clinical outcome measures in hereditary neuromuscular diseases. KU Leuven
In a considerable number of hereditary neuromuscular diseases new therapeutic possibilities are on the horizon or even already available. To be able to measure an effect of these therapies it is crucial to define accurate and reproducible outcome measures. These optimal outcome measures differ between different neuromuscular diseases, and depend on several parameters such as the rate of disease progression and different course and ...